Blog

Blue Star Capital (LSE:BLU) reported a pre-tax loss of £576,576 for the six months ended 31 March 2026, primarily reflecting a loss arising from the settlement and conversion of a loan to its largest portfolio company, SatoshiPay. Despite the interim loss, the company’s cash position improved year-on-year to £79,576. Blue Star also completed a £250,000 fundraising in June, providing management with sufficient working capital for an estimated 12 to 18 months while enabling continued investment across its portfolio.

SatoshiPay investment strengthens blockchain focus

During the reporting period, Blue Star invested a further £694,055 into SatoshiPay through SAFE agreements, increasing its fully diluted ownership interest to at least 58%. SatoshiPay’s Vortex decentralised exchange, which facilitates transactions between stablecoins and local fiat currencies, recorded a peak monthly trading volume of US$11.4 million in January, driven by activity in Brazil. Trading volumes subsequently eased as the company prioritised platform resilience, regulatory compliance and the expansion of additional payment corridors. Vortex is also being rolled out across multiple blockchain networks and new geographic markets, providing scope for renewed transaction growth during the second half of 2026.

Portfolio developments

SatoshiPay also encountered operational challenges after a software exploit affecting Hyperbridge resulted in an exposure of approximately US$250,000, highlighting the risks associated with cross-chain blockchain infrastructure. Elsewhere, Blue Star maintained the carrying values of its investments in Dynasty Media & Gaming and Paidia Gaming, indicating relatively stable valuations across the remainder of its investment portfolio outside its core blockchain payments business.

Outlook

Blue Star’s outlook continues to be constrained by recurring losses and persistent negative operating and free cash flow, although the company retains the benefit of a debt-free balance sheet. Technical indicators also remain weak, with the shares trading well below key moving averages and exhibiting subdued momentum. Valuation support remains limited given the company’s negative earnings and the absence of a dividend.

More about Blue Star Capital

Blue Star Capital plc is an investment company focused on emerging technology businesses, with exposure to blockchain payments, decentralised finance and gaming. Its largest holding is SatoshiPay Ltd, which develops blockchain-based cross-border payment infrastructure, alongside investments in Dynasty Media & Gaming’s business-to-business gaming platform and female-focused esports community Paidia.

The company seeks opportunities in high-growth sectors including stablecoin-powered foreign exchange, decentralised finance and digital gaming. Through SatoshiPay’s ecosystem, including the Vortex platform and related technologies such as Nabla and Pendulum, Blue Star provides investors with exposure to evolving blockchain payment infrastructure and emerging market financial services.

Its investment strategy centres on identifying and supporting early-stage technology companies with global growth potential, particularly in industries where traditional financial and entertainment systems remain fragmented or inefficient.

BSF Enterprise (LSE:BSFA) reported unaudited interim results for the six months ended 31 March 2026, highlighting continued progress across its lab-grown leather, regenerative medicine and cell therapy businesses. During the period, the group advanced its strategy of transitioning from research and development towards commercialisation and clinical execution, strengthening its position in tissue-engineered materials and advanced biotechnology.

Product development gathers momentum

Lab-Grown Leather expanded its portfolio with three product families and introduced T-Rex Leather, a luxury lab-grown material created using synthetic dinosaur DNA. The business also showcased a fully tanned hide and unveiled a designer handbag collaboration. Meanwhile, subsidiary 3D Bio-Tissues broadened its CytoBoost product range and secured a £500,000 supply and technical services agreement with South Korean cultivated meat company Seawith. Kerato also reached the halfway stage of development for its LiQD Cornea biosynthetic implant while continuing work on regulatory approvals and quality management systems.

Funding strengthens growth plans

BSF reported a net loss of £956,625 for the period, with the higher loss reflecting increased legal, collaboration and product development costs, alongside the absence of grant income. To strengthen its financial position, the company secured a £300,000 convertible loan note during the reporting period before raising a further £385,000 through a share placing shortly afterwards. Additional funding completed in June, including another equity placing and a £1 million convertible loan note, is expected to support operations and strategic growth initiatives through 2026 and 2027.

Commercial strategy continues to evolve

The latest developments highlight increasing commercial engagement, broader validation of the group’s technologies and growing interest from strategic partners. BSF continues to strengthen its position across the luxury biomaterials and cellular agriculture sectors, with high-profile product launches, an expanding partnership pipeline and additional funding supporting its long-term commercialisation strategy built around proprietary platforms and differentiated bio-based products.

Outlook

BSF’s outlook remains constrained by ongoing financial losses, negative cash flow and weak technical market indicators, with the shares continuing to trade below key moving averages. Valuation support also remains limited given the company’s loss-making position and the absence of a dividend.

More about BSF Enterprise PLC

BSF Enterprise PLC is a UK-listed biotechnology company focused on tissue-engineered materials and regenerative medicine through its wholly owned subsidiaries 3D Bio-Tissues, Kerato and Lab-Grown Leather. Its activities span bio-based materials, cell culture technologies, cultivated meat applications and medical devices, serving industries including luxury fashion, biopharmaceuticals and corneal transplantation.

Lab-Grown Leather develops scaffold-free leather alternatives using synthetic DNA technology, while 3D Bio-Tissues supplies cell culture enhancement products such as CytoBoost to biotechnology and cultivated meat companies. Kerato is developing LiQD Cornea, a biosynthetic hydrogel implant designed to treat corneal damage without relying on donor tissue, supported by regulatory and grant-funded development programmes.

The group’s strategy focuses on protecting intellectual property, expanding strategic partnerships and accelerating the transition from research into commercial deployment and clinical application. Through a combination of proprietary technologies and relatively low-dilution funding structures, BSF aims to establish a leading position in the cellular agriculture and advanced biomaterials markets.

GCP Infrastructure Investments (LSE:GCP) has completed the refinancing of a portfolio of ground-mounted solar photovoltaic assets, introducing approximately £40 million of senior debt to replace what had previously been a fully equity-funded investment. The refinancing, completed using valuations consistent with the company’s 31 March 2026 net asset value, results in a loan-to-enterprise value ratio of around 38% and is expected to release approximately £40 million in cash as part of GCP’s wider capital recycling strategy.

Asset sales support capital recycling strategy

Alongside the refinancing, GCP is progressing a series of infrastructure disposals, including the sale of an anaerobic digestion asset for around £3 million, two onshore wind projects valued at approximately £10 million and a supported social housing portfolio that is expected to repay about £47 million of outstanding loans. The proceeds will primarily be used to reduce the company’s credit facilities, while surplus capital may be allocated to share buybacks or new investment opportunities in line with its capital allocation policy. With the shares continuing to trade at a significant discount to net asset value, regular share repurchases could account for a meaningful proportion of daily trading activity.

Outlook

GCP’s outlook is supported by a conservative balance sheet, improving cash generation and constructive technical market signals. These strengths are partly offset by uneven revenue performance and a relatively demanding price-to-earnings valuation, although the company’s attractive dividend yield, ongoing share buyback programme and disciplined capital management provide additional support.

More about GCP Infrastructure Investments Ltd

GCP Infrastructure Investments Ltd is a FTSE 250-listed, closed-ended investment company focused on delivering long-term, inflation-linked returns through investments in UK infrastructure debt. The portfolio is concentrated on projects backed by public sector or availability-based revenue streams, with a strong emphasis on infrastructure that delivers positive environmental and social outcomes.

Venture Life (LSE:VLG) delivered revenue of £50.0 million for the 17 months to 31 May 2026, representing a 30.9% increase on the previous reporting period, while pro forma revenue grew 16.0%, driven primarily by higher sales volumes. The company’s Power Brands now generate more than 90% of total revenue, with products including Lift, Balance Activ and Earol recording strong performances following increased marketing investment, new product launches and renewed partnerships with international distributors. Adjusted EBITDA is expected to be in line with market expectations.

AI transformation underpins operational strategy

Venture Life is implementing a digital-first transformation programme centred on Microsoft Dynamics 365, using artificial intelligence to improve demand forecasting, promotional planning and stock-keeping unit management. The company expects the initiative to deliver measurable financial benefits within the next 12 months. Net cash declined to approximately £12.0 million following the acquisitions of FemiClear and CUROXEN, while adjusted free cash flow improved to around £5.9 million. Management believes the group’s balance sheet remains strong enough to support further investment in brand marketing, portfolio optimisation and earnings-accretive acquisitions across its core UK and US markets.

Outlook

Venture Life’s outlook is supported by improving profitability and a significantly strengthened balance sheet with very low debt levels. However, these positives are partly offset by the swing to negative operating and free cash flow during 2025, together with fluctuating revenue and margin performance. Technical indicators remain weak despite oversold conditions, while valuation remains difficult to assess because of the company’s negative price-to-earnings ratio and the absence of a stated dividend yield.

More about Venture Life

Venture Life Group PLC is a UK-listed consumer healthcare company specialising in the innovation, development and commercialisation of products across women’s intimate health, ear care, energy, glucose management and menopause support. Its portfolio of Power Brands includes Balance Activ, Lift, Glucogel, Earol, Health & Her and Health & Him, alongside a growing oncology support range featuring Gelclair and Pomi-T. The company continues to focus its commercial expansion on the UK and US markets.

Chariot (LSE:CHAR) reported its audited 2025 full-year results, marking a year of significant strategic progress as it broadened its upstream oil and gas portfolio while accelerating the growth of its renewable energy business across Africa. With energy security remaining a key global priority, the company is strengthening its position as a supplier of both conventional and low-carbon energy to support the continent’s expanding energy needs.

Upstream portfolio grows across Angola and Morocco

In its upstream business, Chariot increased its exposure to offshore Angolan oil production through assets producing around 40,000 barrels per day. Following completion of the Etu Energias transaction, the company expects to receive cash flow equivalent to approximately 4,000 barrels per day. Chariot also regained operatorship and a 75% working interest in the Lixus and Rissana licences in Morocco, while redesigning the Anchois gas project to reduce capital expenditure without compromising its planned production capacity of up to 105 million standard cubic feet per day. The group also continues to assess additional exploration and new venture opportunities, including acreage in Namibia’s Orange Basin.

Renewable energy business continues to scale

Renewable energy subsidiary Etana Energy is progressing rapidly, with 400 MW of wind and solar capacity currently under construction and a development pipeline exceeding 500 MW. The business has secured long-term power purchase agreements with major industrial customers and financing from leading development finance institutions. Elsewhere, Chariot has interests in 194 MW of wind projects under construction, is advancing solar developments for mining customers in Zambia, South Africa and Zimbabwe, and continues to develop its Project Nour green hydrogen and associated green iron initiatives in Mauritania.

Capital raise supports growth strategy

The company strengthened its financial position through a US$24.3 million placing and open offer completed in March 2026, providing additional funding for upstream expansion and renewable energy development. The board has also proposed a share consolidation designed to reduce the number of ordinary shares in issue and rebase the share price as part of its broader strategy to improve market perception and support future growth.

Outlook

Chariot’s outlook continues to reflect financial challenges and weak technical market indicators, although recent strategic developments, new partnerships and the continued expansion of its renewable energy portfolio provide opportunities for longer-term improvement. The company’s valuation remains under pressure as it continues to report losses.

More about Chariot Limited

Chariot Limited is an Africa-focused energy company with operations spanning upstream oil and gas and renewable power generation. Its hydrocarbon portfolio includes producing, development and exploration assets in Angola and Morocco, alongside new venture opportunities across Africa. Its renewable energy division develops, owns and trades electricity for industrial and mining customers while advancing green hydrogen projects in Mauritania.

Listed on AIM under the ticker CHAR, the company has built a diversified energy platform focused on delivering reliable, competitive and sustainable energy solutions. Through partnerships with major industry participants and development finance institutions, Chariot aims to expand its presence across Africa’s rapidly growing energy markets while supporting both energy security and the transition to lower-carbon power.

Rockhopper Exploration (LSE:RKH) continues to streamline its portfolio as it shifts its strategic focus toward the North Falkland Basin and works to complete its withdrawal from Italy. The company’s long-term strategy is centred on its Falkland Islands assets, including the Sea Lion development, as it moves away from its legacy Italian operations.

Italian disposal remains pending

The planned sale of Italian subsidiary Rockhopper Civita Limited to Zodiac Energy has been delayed after Italian regulatory approval remained outstanding as of 30 June 2026. Although the Falkland Islands Government has already approved the transaction, the agreed long stop date has now expired, allowing either party to terminate the agreement. Despite this, both companies continue working to secure the remaining regulatory consent, leaving the timing and completion of Rockhopper’s exit from Italy uncertain.

Outlook

Rockhopper’s outlook remains constrained by inconsistent operating performance, characterised by minimal revenue generation and recurring operating losses. Technical indicators also remain weak, with the shares trading below key moving averages alongside negative MACD and subdued RSI and stochastic readings. Positive operating and free cash flow recorded during 2024 and 2025, together with a balance sheet supported by shareholder equity, provide some resilience, although higher leverage and volatile operating fundamentals continue to weigh on the investment case.

More about Rockhopper Exploration

Rockhopper Exploration plc is a UK-based oil and gas exploration and production company focused on the Falkland Islands. The group owns a 35% interest in licences within the North Falkland Basin, where development of the Sea Lion field, one of the region’s largest oil discoveries since its 2010 discovery, has been sanctioned. The company’s shares trade on AIM under the ticker RKH.

Kendrick Resources PLC (LSE:KEN) is advancing its southern African rare earth strategy through the Bonya Rare Earth Project in Namibia and the Blue Fox licence in Zambia, with the objective of progressing exploration assets into compliant mineral resources and, ultimately, production. The company’s focus is on supplying critical rare earth elements required by high-tech and industrial sectors.

Teufelskuppe drilling strengthens development outlook

Recent portable X-ray fluorescence (pXRF) results from diamond drilling at the Teufelskuppe rare earth project in Namibia have confirmed extensive high-grade mineralisation and strong continuity of light rare earth elements at depth. Several wide, high-grade intercepts place the carbonatite system among the highest-grade rare earth deposits globally, while work to establish a JORC 2012-compliant mineral resource is progressing. These results strengthen Teufelskuppe’s position as a potential near-term development project capable of becoming an important source of rare earth supply for free-market economies while reinforcing Namibia’s growing role in global critical minerals supply chains.

Exploration programme continues

Drilling activities remain ongoing as Kendrick expands the geological database required for its maiden formal mineral resource estimate. Early findings indicate that the existing 14-million-tonne surface resource could represent only a small portion of the project’s overall mineral potential. With demand for neodymium and praseodymium continuing to grow across permanent magnets, renewable energy systems, electric vehicles and defence applications, the size and grade of the Teufelskuppe rare earth system provide significant long-term development potential.

Outlook

Kendrick Resources continues to face financial challenges, with no revenue generation, ongoing losses, negative cash flow and a balance sheet weakened by negative equity. While technical indicators remain supportive, valuation metrics are difficult to assess because the company is loss-making and does not pay a dividend.

More about Kendrick Resources PLC

Kendrick Resources PLC is a mineral exploration and development company focused on acquiring and advancing rare earth and other mineral assets through exploration, technical evaluation and resource development. The company is progressing the Bonya Rare Earth Project in Namibia and the Blue Fox licence in northwest Zambia, with a strategy of bringing projects toward production through joint ventures, commercial partnerships or asset sales.

Its portfolio is centred on rare earth-bearing carbonatite systems, positioning the company to benefit from increasing demand for critical minerals used in advanced technology, renewable energy and defence industries. The Teufelskuppe project is emerging as a cornerstone asset, benefiting from established infrastructure and an in-house mineral resource currently being upgraded to JORC 2012 compliance.

Oxford BioDynamics (LSE:OBD) delivered modest revenue growth in its interim results, with revenue increasing to £0.69 million while the operating loss narrowed to £4.68 million. A £6.32 million equity fundraising strengthened the balance sheet, lifting period-end cash to £2.51 million. Despite these improvements, the board warned that additional funding will be required by late August 2026, even as demand for its U.S. prostate screening test continues to build.

Orion platform rollout gains momentum

The company recorded a sharp increase in Prostate Screening EpiSwitch (PSE) test volumes and expanded its media profile in the United States during the period. Oxford BioDynamics also introduced its cloud-based EpiSwitch Orion platform, which is already being used by leading research institutions and is under evaluation in discussions with three major pharmaceutical companies. To support commercial execution, the group appointed diagnostics industry veteran Richard Compton as chief executive officer, added a new non-executive director and engaged a third-party sales organisation. These initiatives are intended to accelerate adoption of Orion and additional products, including the ME/CFS blood test, while pursuing non-dilutive funding opportunities and enhancing shareholder value.

Outlook

Oxford BioDynamics continues to face financial headwinds despite improving commercial traction. Persistent losses, elevated leverage and deteriorating free cash flow remain significant challenges, while technical indicators suggest the shares remain in a downtrend, with only limited support from near-oversold momentum signals. Valuation also offers little encouragement, reflecting the company’s loss-making position and the absence of a dividend.

More about Oxford BioDynamics

Oxford BioDynamics is an AIM-listed biotechnology company specialising in precision diagnostic blood tests and its proprietary EpiSwitch 3D genomics platform. Its commercial offering includes the EpiSwitch Prostate Screening test and the Checkpoint Inhibitor Response Test, with operations spanning the UK, United States and Malaysia, alongside an expanding focus on pharmaceutical and biotechnology data partnerships.

The company’s cloud-based EpiSwitch Orion platform transforms standard and legacy sequencing datasets into actionable 3D genomic insights, enabling the analysis of non-coding disease variants that conventional genomics approaches often miss. Supported by an extensive disease-focused knowledge base, Oxford BioDynamics aims to advance drug target discovery, predictive biomarker development and precision medicine across oncology, neurology, inflammatory diseases and other therapeutic areas.

Shuka Minerals (LSE:SKA) used 2025 as a transformational year, implementing board changes, securing additional funding support and advancing its strategy to diversify beyond coal. Meanwhile, the company’s Rukwa coal mine in Tanzania remained under care and maintenance as preparations continued for a planned production restart in the third quarter of 2026. Management is progressing a targeted capital expenditure programme to bring the mine back online, with equipment leasing revenue providing interim support and negotiations continuing with cement and power sector customers for coal supply agreements covering up to 10,000 tonnes per month.

Kabwe acquisition broadens commodity portfolio

During the year, Shuka completed the acquisition of Leopard Exploration and Mining Limited, securing full ownership of the Kabwe Mine in Zambia. The historic lead and zinc operation holds independently verified mineral resources alongside favourable economic projections. Supported by a £2 million funding commitment from major shareholder Gathoni Muchai Investments, the appointment of new independent directors and a staged exploration and development programme, the company is expanding its exposure beyond coal while positioning itself for future growth across East and Central Africa.

Outlook

Shuka’s near-term outlook continues to be shaped by financial pressures and weak technical market signals. Although the Kabwe acquisition provides a potentially significant growth platform, delays in funding and unfavourable valuation metrics remain key factors weighing on investor sentiment.

More about Shuka Minerals Plc

Shuka Minerals Plc is an Africa-focused mining company listed on AIM in London and AltX in Johannesburg. Its portfolio includes the Rukwa coal mine in Tanzania and the recently acquired Kabwe lead-zinc-silver-vanadium project in Zambia, reflecting the company’s strategy of building a more diversified portfolio spanning coal and battery-related metals.

While policymakers kept rates unchanged at 3.5% -3.75%, nine of the 18 officials now expect a rate hike, as inflation projections were revised higher from 2.7% in March to 3.6% by the end of 2026, and to 2.3% for 2027 from 2.2%. 

Much of that deterioration came from events in the Middle East, especially disruptions in the Strait of Hormuz, which hit global energy supplies and pushed oil prices higher. Now that things seem to be easing, with shipping resuming and crude back below $75 a barrel, does that mean inflation could cool fast enough for the Fed to cut rates before year-end?

Not according to the CME FedWatch Tool, where the odds of rates being at 3.25%–3.50% by January 1st, 2027 are… 0%. 

And for good reason.

Although headline PCE inflation accelerated to 4.1% year-over-year in May, while core PCE remained elevated at 3.4% and broadly in line with expectations, both are still well above the Fed’s 2% target. Lower energy prices should eventually help, but policymakers know disinflation doesn’t happen overnight.

On top of that, the U.S. economy continues to hold up well. First-quarter GDP was revised higher to 2.1%, and the University of Michigan Consumer Sentiment Index rose to 49.5 in June from 44.8 in May. While confidence remains weak by historical standards, the direction of travel is positive.

Hence, the dollar (DXY) strengthened, while gold extended its decline.

Now all eyes are on this week’s labor market data. Payroll growth is expected to come in at around 115,000 jobs, down from 172,000 previously. If the numbers disappoint, markets could start pricing in a more dovish Fed. If, in turn, employment stays strong, rate-cut expectations will likely fade further.